Receive periodic news and updates relating to SpringerOpen.
Instructions for authors
See 'About this journal' for descriptions of information about policies and the refereeing process.
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission and peer review. SpringerOpen journals are covered by the Membership scheme.
Please note that Organic and Medicinal Chemistry Letters levies an article-processing charge on all accepted Short communications; if the submitting author's institution is a SpringerOpen member the cost of the article-processing charge may be covered by the membership (see About page for detail). Please note that the membership is only automatically recognised on submission if the submitting author is based at the member institution.
To facilitate rapid publication and to minimize administrative costs, Organic and Medicinal Chemistry Letters prefers online submission.
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time; when users return to the site, they can carry on where they left off.
See below for examples of word processor and graphics file formats that can be accepted for the main manuscript document by the online submission system. Additional files of any type, such as movies, animations, or original data files, can also be submitted as part of the manuscript.
During submission you will be asked to provide a cover letter. Use this to explain why your manuscript should be published in the journal, to elaborate on any issues relating to our editorial policies in the 'About Organic and Medicinal Chemistry Letters' page, and to declare any potential competing interests. You will be also asked to provide the contact details (including email addresses) of potential peer reviewers for your manuscript. These should be experts in their field, who will be able to provide an objective assessment of the manuscript. Any suggested peer reviewers should not have published with any of the authors of the manuscript within the past five years, should not be current collaborators, and should not be members of the same research institution. Suggested reviewers will be considered alongside potential reviewers recommended by the Editor-in-Chief and/or Editorial Board members. If your article is part of a special issue, please note this within your cover letter.
Assistance with the process of manuscript preparation and submission is available from SpringerOpen customer support team.
We also provide a collection of links to useful tools and resources for scientific authors on our Useful Tools page.
The following word processor file formats are acceptable for the main manuscript document:
- Microsoft word (DOC, DOCX)
- Rich text format (RTF)
- Portable document format (PDF)
- DeVice Independent format (DVI)
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if you use TeX format. During the TeX submission process, please submit your TeX file as the main manuscript file and your bib/bbl file as a dependent file. Please also convert your TeX file into a PDF and submit this PDF as an additional file with the name 'Reference PDF'. This PDF will be used by internal staff as a reference point to check the layout of the article as the author intended. Please also note that all figures must be coded at the end of the TeX file and not inline.
If you have used another template for your manuscript, or if you do not wish to use BibTeX, then please submit your manuscript as a DVI file. We do not recommend converting to RTF.
For all TeX submissions, all relevant editable source must be submitted during the submission process. Failing to submit these source files will cause unnecessary delays in the publication procedures.
Preparing main manuscript text
General guidelines of the journal's style and language are given below.
Length of article
Short communications should be between 1,000 and 1,500 words and have no more than 25 references.
Manuscript sections for Short communications
Manuscripts for Short communications submitted to Organic and Medicinal Chemistry Letters should be divided into the following sections (in this order):
- Title page
- List of abbreviations used (if any)
- Competing interests
- Description of additional data files (if any)
- Illustrations and figures (if any)
- Tables and captions (if any)
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
This should list: the title of the article, which should include an accurate, clear and concise description of the reported work, avoiding abbreviations; and the full names, institutional addresses, and email addresses for all authors. The corresponding author should also be indicated.
The abstract of the manuscript should not exceed 250 words and must be structured into separate sections: Background, the context and purpose of the study; Findings, the main methods and results; Conclusions, brief summary and potential implications. Please minimize the use of abbreviations and do not cite references in the abstract.
Three to ten keywords representing the main content of the article.
This section should contain the body of the article, including a brief statement of the research hypothesis, the methods used, and the results found. The findings section can be broken into subsections with short informative headings.
List of abbreviations
If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests; they should also reveal any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
When completing your declaration, please consider the following questions:
Financial competing interests
- In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
- Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
- Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
- Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.
Description of additional data files (if any)
Please provide a brief summary of the additional data files that are accompany the manuscript; this should be done in the form of an "Additional data file" section; the details and descriptions you have provided in the additional data file could be included in this section. This should be in the format of the following example:
"The following additional data are available with the online version of this paper. Additional data file 1 is a table listing the reaction optimization conditions. Additional data file 2 contains full characterization data for the compounds synthesized. Additional data file 3 contains the CIF for compound 1... etc."
You may choose to use this section to include any relevant information about the author(s) that may aid the reader's interpretation of the article, and understand the standpoint of the author(s). This may include details about the authors' qualifications, current positions they hold at institutions or societies, or any other relevant background information. Please refer to authors using their initials. Note this section should not be used to describe any competing interests.
Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible.
Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.
Endnotes should be designated within the text using a superscript lowercase letter and all notes (along with their corresponding letter) should be included in the Endnotes section. Please format this section in a paragraph rather than a list.
All references, including URLs, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, followed by any in tables or legends. Each reference must have an individual reference number. Please avoid excessive referencing. If automatic numbering systems are used, the reference numbers must be finalized and the bibliography must be fully formatted before submission.
Only articles and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited; unpublished abstracts, unpublished data and personal communications should not be included in the reference list, but may be included in the text and referred to as "unpublished observations" or "personal communications" giving the names of the involved researchers. Obtaining permission to quote personal communications and unpublished data from the cited colleagues is the responsibility of the author. Footnotes are not allowed, but endnotes are permitted. Journal abbreviations follow Index Medicus/MEDLINE. Citations in the reference list should include all named authors, up to the first 30 before adding 'et al.'..
Any in press articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.
An Endnote style file is available.
Examples of the Organic and Medicinal Chemistry Letters reference style are shown below. Please ensure that the reference style is followed precisely; if the references are not in the correct style they may have to be retyped and carefully proofread.
Examples of the Organic and Medicinal Chemistry Letters reference style
Article within a journal
Smith J, Jones M Jr, Houghton L (1999) Future of health insurance. N Engl J Med 965:325-329
Article by DOI (with page numbers)
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med 78:74-80. doi:10.1007/s001090000086.
Article by DOI (before issue publication and with page numbers)
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. doi:10.1007/s001090000086
Article in electronic journal by DOI (no paginated version)
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. Dig J Mol Med. doi:10.1007/s801090000086
Journal issue with issue editor
Smith J (ed) (1998) Rodent genes. Mod Genomics J 14(6):126-233
Journal issue with no issue editor
Mod Genomics J (1998) Rodent genes. Mod Genomics J 14(6):126-233
Book chapter, or an article within a book
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York
Complete book, authored
South J, Blass B (2001) The future of modern genomics. Blackwell, London
Complete book, edited
Smith J, Brown B (eds) (2001) The demise of modern genomics. Blackwell, London
Complete book, also showing a translated edition [Either edition may be listed first.]
Adorno TW (1966) Negative Dialektik. Suhrkamp, Frankfurt. English edition: Adorno TW (1973) Negative Dialectics (trans: Ashton EB). Routledge, London
Chapter in a book in a series without volume titles
Schmidt H (1989) Testing results. In: Hutzinger O (ed) Handbook of environmental chemistry, vol 2E. Springer, Heidelberg, p 111
Chapter in a book in a series with volume titles
Smith SE (1976) Neuromuscular blocking drugs in man. In: Zaimis E (ed) Neuromuscular junction. Handbook of experimental pharmacology, vol 42. Springer, Heidelberg, pp 593-660
OnlineFirst chapter in a series (without a volume designation but with a DOI)
Saito, Yukio, and Hyuga, Hiroyuki. (2007) Rate equation approaches to amplification of enantiomeric excess and chiral symmetry breaking. Topics in Current Chemistry. doi:10.1007/128_2006_108.
Proceedings as a book (in a series and subseries)
Zowghi D (1996) A framework for reasoning about requirements in evolution. In: Foo N, Goebel R (eds) PRICAI'96: topics in artificial intelligence. 4th Pacific Rim conference on artificial intelligence, Cairns, August 1996. Lecture notes in computer science (Lecture notes in artificial intelligence), vol 1114. Springer, Heidelberg, p 157
Article within conference proceedings with an editor (without a publisher)
Aaron M (1999) The future of genomics. In: Williams H (ed) Proceedings of the genomic researchers, Boston, 1999
Article within conference proceedings without an editor (without a publisher)
Chung S-T, Morris RL (1978) Isolation and characterization of plasmid deoxyribonucleic acid from Streptomyces fradiae. In: Abstracts of the 3rd international symposium on the genetics of industrial microorganisms, University of Wisconsin, Madison, 4-9 June 1978
Article presented at a conference
Chung S-T, Morris RL (1978) Isolation and characterization of plasmid deoxyribonucleic acid from Streptomyces fradiae. Paper presented at the 3rd international symposium on the genetics of industrial microorganisms, University of Wisconsin, Madison, 4-9 June 1978
Norman LO (1998) Lightning rods. US Patent 4,379,752, 9 Sept 1998
Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
Book with institutional author
International Anatomical Nomenclature Committee (1966) Nomina anatomica. Excerpta Medica, Amsterdam
In press article
Major M (2007) Recent developments. In: Jones W (ed) Surgery today. Springer, Dordrecht (in press)
Doe J (1999) Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. Available via DIALOG. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999
Healthwise Knowledgebase (1998) US Pharmacopeia, Rockville. http://www.healthwise.org. Accessed 21 Sept 1998
Supplementary material/private homepage
Doe J (2000) Title of supplementary material. http://www.privatehomepage.com. Accessed 22 Feb 2000
Doe J (1999) Title of preprint. http://www.uni-heidelberg.de/mydata.html. Accessed 25 Dec 1999
Doe J (1999) Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt. Accessed 12 Nov 1999
ISSN International Centre (2006) The ISSN register. http://www.issn.org. Accessed 20 Feb 2007
Preparing figures and schemes
Figures and schemes should be provided as separate files and should not be included in the main text of the submitted manuscript, although they may also be embedded in appropriate locations in the text file. Figures should always be cited in text in consecutive numerical order. Schemes must only be embedded in the text file. Each figure or scheme should comprise only a single file. There is no charge for the use of color.
Illustrations should be provided as separate files, not embedded in the text file. Each figure should include a single illustration and should fit on a single page in portrait format. If a figure consists of separate parts, it is important that a single composite illustration file be submitted which contains all parts of the figure. There is no charge for the use of color figures.
The following file formats can be accepted:
- PDF (preferred format for diagrams)
- DOCX/DOC (single page only)
- PPTX/PPT (single slide only)
- PNG (preferred format for photos or images)
- CDX (ChemDraw: preferred format for chemical structures)
- SKC, TGF (ISIS/Draw, Symyx Draw: Accelrys Draw preferred format for chemical structures)
The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file. For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have previously been published elsewhere.
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends may then follow, but they should be concise. Tables should always be cited in text in consecutive numerical order.
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 portrait or landscape format. These will be typeset and displayed in the final published form of the article. Such tables should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned when the file is sent electronically for review; this will not always be the case if columns are generated by simply using tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should not be used to indicate numerical values. Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in a table legend. Tables should not be embedded as figures or spreadsheet files.
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls or .xlsx) or comma separated values (.csv). As with all files, please use the standard file extensions.
Preparing additional files
Although Organic and Medicinal Chemistry Letters does not restrict the length and quantity of data included in an article, we encourage authors to provide datasets, tables, movies, or other information as additional files.
Please note: All Additional files will be published along with the article. Do not include files such as certificates of language editing, or revised versions of the main manuscript document with tracked changes. Such files should be sent by email to firstname.lastname@example.org, quoting the Manuscript ID number.
Results that would otherwise be indicated as "data not shown" can and should be included as additional files. Since many weblinks and URLs rapidly become broken, Organic and Medicinal Chemistry Letters requires that supporting data are included as additional files, or deposited in a recognized repository. Please do not link to data on a personal/departmental website. The maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission.
Additional files can be in any format, and will be downloadable from the final published article as supplied by the author. We recommend CSV rather than PDF for tabular data.
Certain supported files formats are recognized and can be displayed to the user in the browser. These include most movie formats (for users with the Quicktime plugin), mini-websites prepared according to our guidelines, chemical structure files (MOL, PDB), geographic data files (KML).
If additional material is provided, please list the following information in a separate section of the manuscript text:
- File name (e.g. Additional file 1)
- File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL of an appropriate viewer if format is unusual)
- Title of data
- Description of data
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name within the body of the article, e.g. 'An additional movie file shows this in more detail [see Additional file 1]'.
Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely available tools. The following are examples of suitable formats.
- PDF (Adode Acrobat)
- SWF (Shockwave Flash)
- MP4 (MPEG 4)
- MOV (Quicktime)
- XLS, XLSX (Excel Spreadsheet)
- CSV (Comma separated values)
As with figure files, files should be given the standard file extensions.
Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from within the full text HTML version of the article. In order to do this, please follow these instructions:
- Create a folder containing a starting file called index.html (or index.htm) in the root.
- Put all files necessary for viewing the mini-website within the folder, or sub-folders.
- Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My Documents\mini-website\images\picture.jpg") and no link is longer than 255 characters.
- Access the index.html file and browse around the mini-website, to ensure that the most commonly used browsers (Internet Explorer and Firefox) are able to view all parts of the mini-website without problems, it is ideal to check this on a different machine.
- Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the ZIP, and that the file has .zip extension, then submit as an additional file with your article.
Style and language
Currently, Organic and Medicinal Chemistry Letters can only accept manuscripts written in English. Spelling should be US English or British English, but not a mixture.
There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise.
For authors who wish to have the language in their manuscript edited by a native-English speaker with scientific expertise, SpringerOpen recommends Edanz. Springer has arranged a 10% discount to the fee charged to SpringerOpen authors by Edanz. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. Please contact Edanz directly to make arrangements for editing, and for pricing and payment details.
Help and advice on scientific writing
The abstract is one of the most important parts of a manuscript. For guidance, please visit our Author Academy on writing and publishing.
Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of abbreviations can be provided following the main manuscript text.
- Please use double line spacing.
- Type the text unjustified, without hyphenating words at line breaks.
- Use hard returns only to end headings and paragraphs, not to rearrange lines.
- Capitalize only the first word, and proper nouns, in the title.
- All pages should be numbered.
- Use the Organic and Medicinal Chemistry Letters reference format.
- Footnotes are not allowed, but endnotes are permitted.
- Please do not format the text in multiple columns.
- Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full. Please ensure that all special characters used are embedded in the text, otherwise they will be lost during conversion to PDF.
SI units should be used throughout (liter and molar are permitted, however).
Please use the standard mathematical notation for formulae, symbols, etc.:
- Italic for single letters that denote mathematical constants, variables, and unknown quantities
- Roman/upright for numerals, operators, and punctuation, and commonly defined functions or abbreviations, e.g., cos, det, e or exp, lim, log, max, min, sin, tan, d (for derivative)
- Bold italics for vectors, tensors, and matrices.